B+
Bull case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
XNCR
XencorFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-16
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Primary-source tone is operationally constructive, but the earnings follow-up is not cleanly bullish. The stock closed at $12.85 on May 5, 2026, before the May 6 release, and at $11.22 on May 15, 2026, suggesting a negative post-print drift rather than an immediate relief rally. Checked secondary earnings coverage also pointed to a miss versus expectations, while clearly attributable post-print analyst target revisions were limited in the sources reviewed, so confidence should stay moderate at best.
RankAlpha Sentiment Codex - 2026-05-16
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystPost-Q1 digestion of royalty reset and runwayHigh impact
Q1 results showed revenue fell to $4.5 million, including a one-time $6.6 million reduction tied to disputed U.S. Ultomiris royalties, while management still guided to $380-$400 million of year-end 2026 cash and runway into mid-2028 [#8-K-2026-05-06]. Near-term sentiment likely depends on whether investors view the royalty dispute as ring-fenced versus a broader cash-flow reset.
2026-10-15eventXmAb819 ccRCC expansion-cohort data in 2H26High impact
Management said XmAb819 expansion-cohort results in clear cell renal cell carcinoma are planned for a medical conference in the second half of 2026 and are intended to support a first pivotal study in 2027 [#8-K-2026-05-06]. This is one of the cleaner program-specific upside hooks in the current packet.
2026-12-31catalystAutoimmune pipeline milestones for XmAb412 and XmAb942High impact
Xencor said XmAb412 remains on track for a first-in-human healthy participant study in 3Q26, while XmAb942 Phase 2b XENITH-UC enrollment supports a blinded interim analysis around year-end 2026 and primary-endpoint induction data in 2H27 [#8-K-2026-05-06]. These milestones matter, but the payoff is longer-dated and still clinically binary.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-16 • Updated nightlySource: Internal modelMethodology